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Abstract
Introduction: Concentrations of plasma cell-free DNA are increased in various diseases and have shown some
prognostic value in many patient groups, including critically ill patients. Pathophysiological processes behind the
need for mechanical ventilation and the treatment itself could raise plasma levels of cell-free DNA. We evaluated
levels of plasma cell-free DNA and their prognostic value in patients needing mechanical ventilation.
Methods: We studied prospectively 580 mechanically ventilated critically ill patients. Blood samples were taken at
study admission (Day 0) and on Day 2. Plasma cell-free DNA concentrations were measured by real-time
quantitative PCR assay for the b-globin gene and are expressed as genome equivalents (GE)/ml.
Results: Median (interquartile range, IQR) plasma cell-free DNA concentration was 11,853 GE/ml (5,304 to 24,620
GE/mL) at study admission, and 11,610 GE/mL (6,411 to 21,558 GE/mL) on Day 2. Concentrations at admission were
significantly higher in 90-day non-survivors than survivors, 16,936 GE/mL (7,262 to 46,866 GE/mL) versus 10,026 GE/
mL (4,870 to 19,820 GE/mL), P < 0.001. In a multivariate logistic regression analysis plasma cell-free DNA
concentration over 16,000 GE/ml remained an independent predictor of 90-day mortality (adjusted odds ratio 2.16,
95% confidence interval CI 1.37 to 3.40). Positive likelihood ratio of plasma cell-free DNA at admission for the
prediction of 90-day mortality was 1.72 (95% CI 1.40 to 2.11).
Conclusions: Plasma levels of cell-free DNA were significantly higher in non-survivors than survivors. Plasma DNA
level at baseline was an independent predictor of 90-day mortality. However, its clinical benefit as a prognostic
marker seems to be limited.
Introduction
Cell-free DNA is detected in blood in many diseases,
but also in healthy individuals. Cell-free DNA can origi-
nate from necrotic cells or apoptotic processes, and
active release of DNA fragments from living cells has
also been described [1]. The exact mechanism of DNA
occurrence in blood, however, is not fully understood.
Knowledge about the elimination of cell-free DNA from
blood is inadequate [2], but available data suggest that
more than one mechanism is involved in its clearance.
In a recent meta-analysis, based on 39 studies, cell-free
DNA concentrations up to 4,000 genome equivalents
(GE)/ml in healthy controls were reported [3]. Higher
levels have been measured in different pathophysiologi-
cal states: in malignancies [4], sepsis [5,6], acute pan-
creatitis [7,8], trauma [9], stroke [10], myocardial
infarction [11], and abdominal pain [12]. Plasma cell-
free DNA may have prognostic value in many acute
clinical situations: patients with sepsis [6], acute coron-
ary syndrome (ACS) [13], trauma [9], pancreatitis [7],
and in patients after cardiac arrest [14].
The need for mechanical ventilation (MV) is a conse-
quence of diverse pathophysiologic conditions of both
pulmonary and extrapulmonary origin leading to
impaired oxygenation and/or ventilation or a need to
secure the airway and support ventilation because of
impaired consciousness. Deteriorated oxygenation can
per se cause tissue hypoxia and, thus, damage to cells.
In addition, pathophysiologic processes leading to the
need of MV are potentially accompanied with cell death
and the release of DNA to circulation. Furthermore,
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oretically induce release of DNA to circulating plasma.
Association between injurious ventilation and increased
remote organ apoptosis as well as increased type 2 cell
necrosis in lungs has been shown in an animal study
[16]. However, no large-scale human studies regarding
plasma cell-free DNA in patients needing MV have been
published.
The aim of our study was to assess plasma cell-free
DNA concentrations and theirp r o g n o s t i cv a l u eo n9 0 -
day mortality in a large observational multi-centre study
on mechanically ventilated critically ill patients.
Materials and methods
We conducted a prospective, epidemiological cohort
study on patients needing MV in 25 Finnish intensive
care units (ICU) during an eight-week period (from 16
April to 10 June 2007) (The FINNALI study). In this
study we pros-pectively evaluated all patients (≥16
years) treated in ICUs. The study design and epidemio-
logical results have been published previously [17]. In
brief, all patients treated with respiratory support for
more than six hours either with invasive or non-invasive
interface were included in the study. The local ethics
committees approved the study. Informed consent from
patients or surrogates was required for laboratory
samples.
We registered demographic data, underlying risk fac-
tors for the need of MV, physiological and ventilatory
data at the study admission, and medications. The clini-
cal report form (CRF) data were reported as an attach-
ment to the Finnish Intensive Care Consortium routine
dataset which includes data about reason for admission,
severity scorings (Simplified Acute Physiology Score
(SAPS) II [18] and Sequential Organ Failure Assessment
(SOFA) score [19]), and hospital outcome. Acute lung
injury (ALI) and acute respiratory distress syndrome
(ARDS) were defined according to the American-Eur-
opean Consensus Conference (AECC) criteria [20].
Patients were divided to those who had infection and
those who did not by Acute Physiology and Chronic
Health evaluation (APACHE) III, ICD10-diagnoses
(International Statistical Classification of Diseases and
Related Health Problems), and the presence of pneumo-
nia or sepsis as an underlying risk factor during the pre-
ceding 48 hours. Data collection was accomplished with
an Internet-based interface. Mortality data were
obtained from Statistics Finland [21]. This study is a
prospective sub-study evaluating plasma cell-free DNA
in the FINNALI cohort.
Blood sampling
Two blood samples were drawn: first at the time of
study inclusion (Day 0, sample A) and second in the
morning of Day 2 (sample B) to 10 ml heparin contain-
ing tubes. Plasma was separated as soon as possible by
centrifugation at 1,500 g for 15 minutes and transferred
to acid-handled plastic tubes, which were stored at a
minimum of -20°C in each hospital until the study com-
pletion. All samples were collected at Helsinki Univer-
sity Central Hospital and stored at -80°C.
Quantification of plasma cell-free DNA
DNA extraction and quantification of plasma cell-free
DNA were performed as described earlier [6,22]. Briefly,
plasma samples were centrifuged at 16,000 g for 10 min-
utes before DNA extraction to remove any residual cells
[23]. DNA was extracted using the QIAamp DNA Blood
Mini Kit (Qiagen, Hilden, Germany) according to the
“blood and body fluid protocol”, and plasma cell-free
DNA was measured by real-time quantitative PCR assay
for the b-globin gene. A 10-fold serial dilution of
human genomic DNA (Roche Diagnostics GmbH, Man-
nheim, Germany) was used as a standard curve in the
PCR assay. Results are expressed as genome equivalents
(GE)/ml; 1 GE equals 6.6 pikograms of DNA. In this
study, we considered plasma cell-free DNA concentra-
tion of 4,000 GE/ml as an upper limit of normal range,
value obtained from a recent meta-analysis [3].
Statistics
Data are presented as median and interquartile ranges
(IQR, 25
th and 75
th percentiles) or numbers and percen-
tages. The primary endpoint was 90-day mortality. For
comparisons of non-parametric data between survivors
and non-survivors, we used Mann-Whitney U-test. We
assessed the differences in plasma cell-free DNA con-
centrations between different strata according to the
severity of oxygenation impairment, as reflected by the
baseline PaO2/FiO2-ratio. We also compared non-pul-
monary SOFA scores between these strata to find out
whether there was a correlation between impaired oxy-
genation and failure of other organ systems. We first
used the Kruskal-Wallis test and then the post hoc
Mann-Whitney test with P < 0.01 considered as signifi-
cant due to multiple comparisons. The Spearman’s rank
correlation test was performed to evaluate the associa-
tion between plasma DNA at admission, baseline pH,
renal SOFA points at Day 1, SAPS II score, baseline
PaO2/FiO2-ratio, and baseline tidal volume per predicted
body weight. We analyzed the receiver operating charac-
teristic (ROC) curve for plasma cell-free DNA at admis-
sion for 90-day mortality prediction. For calculations of
sensitivity, specificity and positive likelihood ratios (with
95% confidence intervals, CI) of plasma cell-free DNA
for prediction of 90-day mortality we used two cutoff
points, one obtained from the earlier study [6] and one
f r o mt h ep r e s e n ts t u d yb yY o u d e n ’s method [24]. For
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tality we performed a multivariate backward logistic
regression analysis. Variables included in the analysis
were: plasma cell-free DNA over the best cutoff value at
admission, present infection, and all variables found to
be independent predictors for 90-day mortality in the
FINNALI study (SAPS II score minus oxygenation,
chronic heart disease, suspected aspiration, intoxication,
and baseline PaO2/FiO2-ratio). We also made another
multivariate backward logistic regression analysis with
otherwise same variables, but plasma cell-free DNA was
included as a categorical variable divided to arbitrary
intervals of 5,000 GE/ml. We constructed Kaplan-Meier
curves of 90-day survival according to plasma cell-free
DNA at admission. Finally,w ep e r f o r m e das u b g r o u p
analysis excluding cardiac surgery patients and including
only patients with an emergency admission and invasive
ventilation exceeding 24 hours. We compared the
plasma DNA levels of this subgroup to the rest of the
study patients by the Mann-Whitney test. In all analyses,
P < 0.05 was considered as significant.
Results
Study patients
The study flowchart is presented in Figure 1. Of 958
patients in the FINNALI study, all 580 patients (61%)
with consent given for laboratory samples and at least
sample A (at study admission) available were included
to this study. Sample A was drawn six hours (median,
IQR 6 to 8 hours) and sample B 42 hours (median, IQR
38 to 47 hours) after the start of ventilatory support.
Study patients were older (65 vs. 60 yrs.) and more
often elective admissions (17 vs. 9%), but did not differ
significantly from the rest of the FINNALI study
patients in gender, hospital or 90-day mortality, SAPS II
score, SOFA score at 24 hours, operative status, or ven-
tilatory support time (data not shown).
Characteristics of the study patients divided into sub-
groups are presented in Table 1, and baseline physiologi-
cal characteristics in Table 2. Predisposing factors for the
need of MV among 580 patients were: surgery in 229
(39%), decreased level of consciousness in 146 (25%), car-
diac insufficiency in 128 (22%), suspected aspiration in 58
(10%) and witnessed aspiration in 29 (5%), sepsis in 82
(14%), pneumonia in 68 (12%), other respiratory infection
in 60 (10%), intoxication in 34 (6%), massive transfusion
in 31 (5%), severe trauma in 29 (5%), acute pancreatitis in
20 (3%), and neuromuscular disease in 16 (3%) patients.
Invasive ventilation was used in 506 of 580 study patients
(87%). Of 229 postoperative patients, 99 (43%) were elec-
tive admissions, mostly (64 patients, 65%) for cardiac sur-
gery. Hospital and 90-day mortalities were 134 (23%, 95%
CI 20 to 27%) and 169 (29%, 95% CI 25 to 33%) of the
580 patients, respectively.
Concentrations of plasma cell-free DNA
In the 580 patients, median (IQR) plasma cell-free DNA
concentration was 11,853 GE/mL (5,304 to 24,620 GE/
mL) in sample A and 11,610 GE/mL (6,411 to 21,558
GE/mL) in sample B. Of the 580 patients, 428 (82%)
had a plasma cell-free DNA concentration at admission
(sample A) that was higher than normal (4,000 GE/ml).
In postoperative patients (N = 229), the median plasma
cell-free DNA concentration (IQR) at admission was
11,436 GE/ml (5,587 to 20,379 GE/ml); in non-operative
patients (N = 351), the median (IQR) concentration at
admission was 12,156 GE/ml (4,938 to 27,292 GE/ml) (P
= 0.36). The change in plasma cell-free DNA concentra-
tion from sample A to sample B was different in post-
operative (rising) and non-operative (descending)
patients (P < 0.01). Non-operative patients with infec-
tion (N = 124) had significantly higher plasma cell-free
DNA concentration at admission than those without
infection (N = 227): median (IQR) 15,859 GE/ml (7,882
to 32,887 GE/ml) vs. 9,500 GE/ml (4,142 to 23,386 GE/
ml) (P < 0.001), respectively. In postoperative patients
the corresponding values did not differ between patients
with infection (N = 55) or without it (N = 174): median
(IQR) 12,560 GE/ml (7,278 to 28,662 GE/ml) vs. 9,595
GE/ml (5,264 to 19,667 GE/ml) (P =0 . 0 5 3 ) ,r e s p e c -
tively.
The median (IQR) plasma cell-free DNA concentra-
tion at admission was significantly higher in 90-day
non-survivors than survivors: 16,936 GE/mL (7,262 to
46,866 GE/mL) vs. 10,026 GE/mL (4,870 to 19,820 GE/
mL) (P < 0.001). In the sample B the difference was not
significant: median (IQR) 12,157 GE/mL (6,722 to
25,933 GE/mL) in 90-day non-survivors vs. 11,556 GE/
mL (5,962 to 19,735 GE/mL) in survivors (P = 0.094).
The difference at admission was statistically significant
in non-operative patients, but not in postoperative
patients (Figure 2).
Plasma cell-free DNA concentrations according to
baseline PaO2/FiO2-ratio are presented in Figure 3.
Non-pulmonary SOFA scores did not differ between
these groups of baseline PaO2/FiO2-ratio (P = 0.389).
Patients with a PaO2/FiO2-ratio lower than 300 mmHg
(N = 356) had significantly higher plasma DNA concen-
trations compared to patients with a PaO2/FiO2-ratio
higher than 300 mmHg (N = 199), median (IQR) 13,381
GE/mL (6,628 to 27,577 GE/mL) vs. 8,314 GE/mL
(3,946 to 19,018 GE/mL) (P < 0.001), respectively. Con-
centrations did not differ between patients with ALI/
ARDS (N = 47) and those without (N = 533): median
(IQR) 13,707 GE/mL (7,700 to 35,596 GE/mL) vs.
11,562 GE/mL (5,171 to 24,130 GE/mL) (P = 0.06),
respectively. Plasma DNA at admission correlated with a
PaO2/FiO2-ratio at baseline (P < 0.001), baseline pH (P
< 0.001), renal SOFA score at Day 1 (P < 0.001), and
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predicted body weight (P = 0.47)
Predictive value of plasma cell-free DNA
The area under the ROC curve (AUC) for plasma cell-
free DNA concentration at admission as a predictor of
90-day mortality was 0.624 (95% CI 0.572 to 0.676); for
the highest plasma cell-free DNA concentration the
AUC was 0.605 (95% CI 0.552 to 0.657). The AUC was
0.643 (95% CI 0.581 to 0.704) in non-operative patients,
0.571 (95% CI 0.469 to 0.673) in post-operative patients,
and 0.609 (95% CI 0.544 to 0.674) in patients with a
All FINNALI
patients
N = 958
No blood samples
N = 333/958 (35%)
- no consent 302/333 (91%)
- missing/inadequate plasma
sample 31/333 (9%)
Blood samples
available
N =  625/958 (65%)
B only
N = 45
A + B (N = 489)
or A only (N = 91)
N = 580/958 (61%)
Nonsurvivors
N = 169/580
(29%)
Survivors
N = 411/580
(71%)
Figure 1 Flowchart of study patients. (A) Blood sample at study admission (Day 0); (B) blood sample at Day 2.
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best cut-off value for prediction of 90-day mortality was
16,000 GE/ml. Sensitivity, specificity and positive likeli-
hood ratios of the best cut-off value in plasma cell-free
DNA concentration at admission are presented in Table
3 with a comparison to the cut-off value from an earlier
study [6].
In the first multivariate analysis, the following factors
were independent predictors of 90-day mortality: plasma
cell-free DNA concentration over 16,000 GE/ml at
admission (P = 0.001), baseline PaO2/FiO2-ratio (P =
0.004), chronic heart disease (P < 0.001), and SAPS II
score minus oxygenation (P < 0.001). The adjusted odds
ratio (95% CI) for plasma cell-free DNA exceeding
16,000 GE/ml at admission was 2.22 (1.41 to 3.48) (Table
3). In the second multivariate analysis, plasma cell-free
DNA divided into intervals of 5,000 GE/ml was a signifi-
cant predictor of 90-day mortality (P =0 . 0 0 1 ) .O t h e r
variables found to be significant in this second multivari-
ate analysis were the same as in the first analysis.
Kaplan-Meier survival curves for 90-day mortality
according to the best cut-off value (16,000 GE/mL) are
presented in Figure 4.
In the subgroup analysis of emergency patients with
invasive ventilation exceeding 24 hours (N = 301), the
median plasma cell-free DNA (IQR) at admission was
12,034 GE/ml (4,924 to 27,091 GE/ml) vs. 11,642 GE/ml
(5,636 to 22,374 GE/ml) in other patients (N = 279) (P
=0 . 5 7 ) .T h eA U Cf o rt h eb a s e l i n ep l a s m aD N Aa sa
predictor of 90-day mortality in this subgroup was 0.641
(95% CI 0.573 to 0.708).
Discussion
To our knowledge, this is the largest multi-centre study
evaluating plasma cell-free DNA concentrations in criti-
cally ill patients. We found that plasma cell-free DNA
concentration at admission in mechanically ventilated
patients was significantly higher in 90-day non-survivors
than survivors. In addition, plasma cell-free DNA at
Table 1 Characteristics of the study patients
All patients
N = 580
Postoperative patients
N = 229
Non-operative patients
Infection
N = 124
No infection
N = 227
Age 61 (51, 74) 69 (56, 76) 63 (55, 73) 62 (48, 74)
Male, n (%) 382 (66) 150 (66) 85 (69) 147 (65)
SAPS II 42 (30, 55) 33 (26, 46) 42 (34, 54) 51 (36, 63)
SOFA at 24 hours 8 (5, 10) 7 (5, 9) 7 (5, 10) 8 (6, 10)
Max SOFA total 9 (6,12) 9 (6, 11) 10 (6, 14) 9 (6, 12)
Invasive ventilation, days 2 (1, 4) 2 (1, 4) 2 (0, 5) 2 (1, 4)
Length of stay, ICU, days 3.2 (1.7, 6.8) 2.9 (1.7, 7.1) 5.0 (2.6, 7.7) 2.7 (1.6, 5.8)
Hospital mortality, n (%) 134 (23) 33 (14) 37 (30) 64 (28)
90-day mortality, n (%) 169 (29) 44 (19) 44 (36) 81 (36)
Data are presented in numbers (percentages) or median (interquartile range).
SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assessment; ICU, intensive care unit
Table 2 Physiological characteristics of the study patients
at baseline
All patients (N = 580)
PaO2/FiO2-ratio 247 (172, 338)
Tidal volume/Predicted body weight 8.6 (7.5, 9.9)
PEEP 6 (5, 8)
MAP 76 (67, 86)
CVP 9 (7, 13)
MV (intubated) 485 (84%)
Vasopressors 304 (52%)
Data are presented in numbers (percentages) or median (interquartile range).
CVP, central venous pressure; MAP, mean arterial pressure; MV, mechanical
ventilation; PEEP, positive end expiratory pressure
Figure 2 Plasma cell-free DNA at admission in 90-day non-
survivors and survivors according to operative status. Data are
presented as median values (lines) with 25
th and 75
th (boxes) and
5th and 95th percentiles (whiskers). Sample A obtained at
admission. GE, genome equivalents; NS, non-significant.
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increments of 5,000 GE/ml) was an independent predic-
tor of 90-day mortality.
In previous studies, concentrations of plasma cell-
free DNA have shown wide distribution. This variation
may partly be explained by the use of multiple meth-
ods in DNA measurements. The problem is evident
when exploring values reported in the control groups
of healthy individuals [3]. The lack of a standardised
method is also a reason why limits of normal values
do not exist. Also, overlapping in cell-free DNA con-
centrations between healthy individuals and patients
exists. For example, in the study of Rainer and collea-
gues, median plasma cell-free DNA concentration has
been up to 1,170 GE/mL in patients with acute coron-
ary syndrome [13], values being at the same level than
measured in healthy individuals. In critically ill patients
with severe sepsis or septic shock, a median plasma
cell-free DNA concentration of 8,070 GE/mL was mea-
sured at admission [6], the analyses done in the same
laboratory with the same method than in the present
study. Patients with major trauma have had median
plasma cell-free DNA concentrations over 181,000 GE/
mL [9]. Kocsis and colleagues have found that levels of
plasma cell-free DNA were significantly higher in
severe acute pancreatitis than in the mild form of the
same disease [8]. In their study, concentrations in the
severe form of acute pancreatitis were high (median
989 ng/ml (149,848 GE/mL)) as were the concentra-
tions in septic shock (median 3,303 ng/ml (500,454
GE/mL)). In the present study, the median concentra-
tion of plasma cell-free DNA at admission was 11,853
GE/mL, which was markedly lower than the levels in
the Kocsis study [8].
In animal studies, isoprenaline has been shown to
induce cell death and apoptosis in myocardial and skele-
tal myocytes in vivo in rats [25]. In clinical situations,
adrenergic stress associated with critical illness itself and
also catecholamines used may contribute to the release
of DNA to circulation. Increased level of plasma DNA
has been measured in healthy volunteers after excessive
training, possibly reflecting an inflammatory reaction
due to anaerobic metabolism [26]. We found a correla-
tion between pH and plasma DNA at admission, a find-
ing possibly reflecting the severity of illness and/or
anaerobic tissue metabolism. A previous study has
reported correlation between plasma cell-free DNA and
SOFA score as a marker of multiple organ dysfunction
and severity of illness [5]. Our results showed positive
correlation between plasma DNA and SAPS II score and
were consistent with that study. Thus, high levels of
p = 0.001
p = 0.007
p < 0.001
NS
NS
NS
Figure 3 Plasma cell-free DNA at admission according to
baseline PaO2/FiO2-ratio based on SOFA cut-offs. Data are
presented as median values (lines) with 25
th and 75
th percentiles
(boxes) and 5
th and 95
th percentiles (whiskers). Sample A obtained
at admission. Comparison between groups by Kruskal-Wallis test (P
< 0.001). Post hoc analyses between groups by Mann-Whitney test
(P < 0.01 considered significant due to multiple comparisons). GE,
genome equivalents; NS, non-significant; SOFA, Sequential Organ
Failure Assessment.
Table 3 Comparison of two different cut-off points of
plasma cell-free DNA for prediction of 90-day mortality
Cut-off point, GE/ml 12,000
(Saukkonen 2008 [6])
16,000
(present study)
Sensitivity 0.60 (0.53 to 0.68) 0.53 (0.45 to 0.60)
Specificity 0.55 (0.50 to 0.60) 0.69 (0.65 to 0.74)
Positive likelihood ratio 1.33 (1.13 to 1.57) 1.72 (1.40 to 2.11)
Odds ratio unadjusted 1.84 (1.28 to 2.65) 2.52 (1.31 to 4.83)
Odds ratio adjusted 1.39 (0.89 to 2.16) 2.22 (1.41 to 3.48)
Data (at admission) presented with 95% confidence intervals
GE, genome equivalents
Figure 4 Kaplan-Meier survival curves for 90-day mortality
according to plasma cell-free DNA cut-off point at admission.
Sample A obtained at admission. GE, genome equivalents.
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critical illness regardless of the specific diagnosis.
However, it is also possible that the observed high con-
centrations of plasma cell-free DNA in our study were
caused by impaired oxygenation in particular. We found a
correlation between the plasma cell-free DNA concentra-
tion and the severity of oxygenation problem (as reflected
by the PaO2/FiO2-ratio) at study inclusion. In general, the
lower was the PaO2/FiO2-ratio, the higher was the plasma
cell-free DNA concentration. Moreover, non-pulmonary
SOFA scores were comparable in different groups of
PaO2/FiO2-ratio, suggesting the i n d e p e n d e n te f f e c to f
impaired oxygenation on plasma cell-free DNA. This asso-
ciation has a physiological rationale as hypoxemia may
cause tissue hypoxia and cell death. Unfortunately, we did
not measure any other indicators of tissue hypoxia, for
example, lactate concentration [27]. A previous study has
shown a correlation between plasma cell-free DNA and
lactate levels in patients with acute mesenteric ischemia,
supporting the connection with tissue hypoxia and plasma
DNA concentration [28].
Large tidal volumes are known to associate with the
development of lung injury [15]. During the last decade,
a lung protective ventilatory strategy with low tidal
volumes (< 6 ml/kg) and plateau pressures (≤30
cmH2O) has been recommended in ALI/ARDS and sep-
sis [29]. In Finland, these recommendations have been
adopted in practise only partly, since tidal volumes have
been higher than recommended especially when calcu-
lated per predicted body weight (PBW) [17]. In the pre-
sent study, we did not find a correlation between the
plasma cell-free DNA concentration at admission and
baseline tidal volume per predicted body weight. Thus,
we could not confirm the association with large tidal
volume and lung injury using plasma cell-free DNA as a
surrogate of lung injury. However, the nature of the pre-
sent study was observational and not designed to study
this association. Neither did we find differences in
plasma cell-free DNA concentrations between patients
with or without ALI/ARDS. In theory, injured vascular
endothelium and alveolar epithelium in ALI and ARDS
could raise plasma cell-free DNA. The blood sampling
(at admission and on Day 2) may have been too early to
find the possible connection with ALI/ARDS, which
often develops later. Instead, the concentration of
plasma cell-free DNA at admission was significantly
higher in patients with infection than without which is
in accordance with earlier studies [5,6].
An earlier study found that cell-free DNA is rapidly
eliminated from the blood [30]. On the other hand,
plasma DNA concentrations have been found to be
increased at 96 hours after the end of excessive training
in healthy volun-teers, possibly associated with an
ongoing inflammatory state [26]. In the present study,
plasma samples were taken at two time points, at study
inclusion and 36 hours later, and concentrations were at
the same level in both samples. This observation may be
explained by continuous release of DNA to circulation.
The significance of renal function is not fully under-
stood, but in the light of an earlier study, renal function
s h o u l dn o ta f f e c tc o n c e n t r a tions [31]. In the present
study, we found a correlation between renal SOFA score
at Day 1 and plasma DNA at admission. However, in
this study we cannot confirm or refute any causality
between these factors.
In non-operative patients, concentrations of plasma
cell-free DNA were higher in non-survivors than in sur-
vivors. In post-operative patients, there was no differ-
ence between non-survivors and survivors. One
plausible explana-tion is that surgery per se may cause
tissue injury that raises plasma cell-free DNA concentra-
tions even when the disease process is not potentially
life-threatening. In this study plasma cell-free DNA con-
centrations of post-operative patients were comparable
to those of non-operative patients, despite a remarkably
lower severity of illness (SAPS II score) of the post-
operative patients. In addition, non-operative patients
may have suffered their insult for a longer period of
time ago than post-operative patients and, thus, plasma
cell-free DNA may be more indicative of cell damage.
Rising concentrations of plasma DNA in sample B in
post-operative, but not in non-operative patients, sug-
gests this possibility.
We found significantly higher plasma cell-free DNA
concentrations at admission in 90-day non-survivors
than survivors. A concentration over 16,000 GE/ml, and
separately increments of 5,000 GE/ml, were independent
predictors of 90-day mortality. However, the AUC for
the prediction of 90-day mortality was poor. Further-
more, we found that sensitivity, specificity, and positive
likelihood ratio were all lower when used in the group
of mechanically ventilated patients than in sepsis
patients [6]. In some earlier studies, the predictive value
of plasma cell-free DNA has been better [5,9,10,13].
However, in these studies follow-up times have varied
and the patient numbers may have been inadequate for
the prediction of mortality.
Limitations
Our study has some limitations. First, our cohort of
patients was inevitably heterogeneous. As a result, it is
possible that some underlying conditions, (for example,
occult neoplasia, pregnancy, autoimmune disorders,
trauma), may have had an unexpected impact on plasma
cell-free DNA values. This heterogeneity is, however,
the situation in real life. In addition, the results from
the analysis of the subgroup with more severely
impaired oxygenation showedt h a tm o r es t r i c tc r i t e r i a
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our findings. Second, we measured plasma DNA only at
two points, both presumably near the onset of disease.
More remote sampling would possibly have provided
information about the association to development of
ARDS and the healing process. However, our aim was
to specifically concentrate on prog-nostication, and,
thus, early sampling independent of clinical treatment
choices is essential. Finally, the present study is ob-ser-
vational by its nature and, thus, could not confirm or
refute any causalities.
Conclusions
In conclusion, we found that plasma cell-free DNA
values are commonly high in mechanically ventilated
patients. Concentrations measured at admission were
higher in 90-day non-survivors than survivors, and pre-
dicted indepen-dently 90-day mortality. However, an
increased plasma cell-free DNA concentration is neither
a sensitive nor a specific predictor of death. Thus, the
clinical usefulness of this test seems to be limited.
Key messages
￿ Plasma cell-free DNA is commonly increased in
patients needing mechanical ventilation.
￿ Plasma cell-free DNA levels are higher in 90-day
non-survivors than survivors.
￿ However, the predictive value of 90-day mortality
in mechanically ventilated patients seems to be poor.
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